DPH7

Summary

DPH7 (diphthamide biosynthesis 7, HGNC:25199) is a protein-coding gene on chromosome 9q34.3, encoding Diphthine methyltransferase (Q9BTV6). Catalyzes the demethylation of diphthine methyl ester to form diphthine, an intermediate diphthamide biosynthesis, a post-translational modification of histidine which occurs in translation elongation factor 2 (EEF2) which can be ADP-ribosylated by diphtheria toxin and by Pseudo….

Diphthamide is a post-translationally modified histidine residue present in elongation factor 2, and is the target of diphtheria toxin. This gene encodes a protein that contains a WD-40 domain, and is thought to be involved in diphthamide biosynthesis. A similar protein in yeast functions as a methylesterase, converting methylated diphthine to diphthine, which can then undergo amidation to produce diphthamide.

Source: NCBI Gene 92715 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 107 total — 2 pathogenic, 1 likely-pathogenic
• MANE Select transcript: NM_138778

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25199
Approved symbol	DPH7
Name	diphthamide biosynthesis 7
Location	9q34.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ90634, RRT2
Ensembl gene	ENSG00000148399
Ensembl biotype	protein_coding
OMIM	613210
Entrez	92715

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 13 protein_coding_CDS_not_defined, 3 protein_coding

ENST00000277540, ENST00000460572, ENST00000467243, ENST00000467768, ENST00000470855, ENST00000472113, ENST00000475100, ENST00000476303, ENST00000477690, ENST00000479650, ENST00000481839, ENST00000485189, ENST00000491359, ENST00000497237, ENST00000872889, ENST00000954472

RefSeq mRNA: 28 — MANE Select: NM_138778 NM_001346370, NM_001346371, NM_001346372, NM_001346373, NM_001346374, NM_001346375, NM_001346376, NM_001346377, NM_001346378, NM_001346379, NM_001346380, NM_001346381, NM_001346382, NM_001346383, NM_001346384, NM_001346385, NM_001346386, NM_001346387, NM_001346388, NM_001346389, NM_001346390, NM_001346391, NM_001346392, NM_001346393, NM_001346394, NM_001346395, NM_001346396, NM_138778

CCDS: CCDS7047

Canonical transcript exons

ENST00000277540 — 9 exons

Exon	Start	End
ENSE00001291947	137554444	137555648
ENSE00001314922	137578625	137578925
ENSE00003469396	137576080	137576167
ENSE00003488899	137564434	137564606
ENSE00003580391	137565085	137565154
ENSE00003603357	137577470	137577603
ENSE00003620271	137564893	137564958
ENSE00003629678	137574752	137574843
ENSE00003676748	137574208	137574380

Expression profiles

Bgee: expression breadth ubiquitous, 206 present calls, max score 96.39.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.7459 / max 128.3385, expressed in 1733 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
103383	9.7459	1733

Top tissues by expression

236 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	96.39	gold quality
body of pancreas	UBERON:0001150	95.88	gold quality
apex of heart	UBERON:0002098	95.41	gold quality
right hemisphere of cerebellum	UBERON:0014890	95.12	gold quality
cerebellar hemisphere	UBERON:0002245	94.72	gold quality
endocervix	UBERON:0000458	94.66	gold quality
left ovary	UBERON:0002119	94.59	gold quality
cerebellar cortex	UBERON:0002129	94.52	gold quality
right ovary	UBERON:0002118	94.48	gold quality
adenohypophysis	UBERON:0002196	94.43	gold quality
body of uterus	UBERON:0009853	94.32	gold quality
right testis	UBERON:0004534	93.95	gold quality
left lobe of thyroid gland	UBERON:0001120	93.64	gold quality
lower esophagus mucosa	UBERON:0035834	93.64	gold quality
muscle layer of sigmoid colon	UBERON:0035805	93.57	gold quality
left testis	UBERON:0004533	93.55	gold quality
right lobe of thyroid gland	UBERON:0001119	93.52	gold quality
ectocervix	UBERON:0012249	93.52	gold quality
metanephros cortex	UBERON:0010533	93.47	gold quality
pituitary gland	UBERON:0000007	93.46	gold quality
granulocyte	CL:0000094	93.40	gold quality
cerebellum	UBERON:0002037	93.32	gold quality
nerve	UBERON:0001021	93.29	gold quality
tibial nerve	UBERON:0001323	93.29	gold quality
mucosa of stomach	UBERON:0001199	93.18	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	92.95	gold quality
body of stomach	UBERON:0001161	92.94	gold quality
spleen	UBERON:0002106	92.84	gold quality
right frontal lobe	UBERON:0002810	92.77	gold quality
small intestine Peyer’s patch	UBERON:0003454	92.74	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.94

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

12 targeting DPH7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-374C-5P	99.80	72.06	2910
HSA-MIR-655-3P	99.80	72.19	2909
HSA-MIR-488-3P	99.61	68.79	1731
HSA-MIR-302A-5P	99.39	68.21	1913
HSA-MIR-4478	99.07	65.16	2320
HSA-MIR-5001-3P	98.91	67.28	1394
HSA-MIR-6829-5P	98.86	65.12	1480
HSA-MIR-2276-3P	98.76	67.75	1384
HSA-MIR-3929	98.32	65.58	1026
HSA-MIR-4469	97.93	65.81	1319

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	dph7	ENSDARG00000062083
mus_musculus	Dph7	ENSMUSG00000026975
rattus_norvegicus	Dph7	ENSRNOG00000008102
drosophila_melanogaster	CG3184	FBGN0029892

Protein

Protein identifiers

Diphthine methyltransferase — Q9BTV6 (reviewed: Q9BTV6)

Alternative names: Diphthamide biosynthesis protein 7, WD repeat-containing protein 85

All UniProt accessions (1): Q9BTV6

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the demethylation of diphthine methyl ester to form diphthine, an intermediate diphthamide biosynthesis, a post-translational modification of histidine which occurs in translation elongation factor 2 (EEF2) which can be ADP-ribosylated by diphtheria toxin and by Pseudomonas exotoxin A (Eta).

Subunit / interactions. Interacts with INCA1.

Pathway. Protein modification; peptidyl-diphthamide biosynthesis.

Similarity. Belongs to the DPH7 family.

RefSeq proteins (28): NP_001333299, NP_001333300, NP_001333301, NP_001333302, NP_001333303, NP_001333304, NP_001333305, NP_001333306, NP_001333307, NP_001333308, NP_001333309, NP_001333310, NP_001333311, NP_001333312, NP_001333313, NP_001333314, NP_001333315, NP_001333316, NP_001333317, NP_001333318, NP_001333319, NP_001333320, NP_001333321, NP_001333322, NP_001333323, NP_001333324, NP_001333325, NP_620133* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001680	WD40_rpt	Repeat
IPR015943	WD40/YVTN_repeat-like_dom_sf	Homologous_superfamily
IPR019775	WD40_repeat_CS	Conserved_site
IPR036322	WD40_repeat_dom_sf	Homologous_superfamily
IPR052415	Diphthine_MTase	Family

Pfam: PF00400

Enzyme classification (BRENDA):

• EC 3.1.1.97 — methylated diphthine methylhydrolase (BRENDA: 2 organisms, 2 substrates, 0 inhibitors, 0 Km, 0 kcat entries)

Catalyzed reactions (Rhea), 1 shown:

• diphthine methyl ester-[translation elongation factor 2] + H2O = diphthine-[translation elongation factor 2] + methanol + H(+) (RHEA:42656)

UniProt features (12 total): repeat 7, chain 1, modified residue 1, sequence variant 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BTV6-F1	81.62	0.68

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 353

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-5358493	Synthesis of diphthamide-EEF2

MSigDB gene sets: 72 (showing top): GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_UP, SHETH_LIVER_CANCER_VS_TXNIP_LOSS_PAM4, GINESTIER_BREAST_CANCER_ZNF217_AMPLIFIED_DN, BOCHKIS_FOXA2_TARGETS, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_ESTER_BONDS, GOMF_CARBOXYLIC_ESTER_HYDROLASE_ACTIVITY, HATADA_METHYLATED_IN_LUNG_CANCER_UP, REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GINESTIER_BREAST_CANCER_20Q13_AMPLIFICATION_DN, GOBP_PEPTIDYL_HISTIDINE_MODIFICATION, REACTOME_GAMMA_CARBOXYLATION_HYPUSINYLATION_HYDROXYLATION_AND_ARYLSULFATASE_ACTIVATION, REACTOME_SYNTHESIS_OF_DIPHTHAMIDE_EEF2, chr9q34, CEBPZ_TARGET_GENES

GO Biological Process (1): protein histidyl modification to diphthamide (GO:0017183)

GO Molecular Function (3): diphthine methylesterase activity (GO:0061685), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (1): cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
peptidyl-histidine modification	1
carboxylic ester hydrolase activity	1
binding	1
catalytic activity	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

540 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DPH7	EEF2	P13639	934
DPH7	DPH1	Q9BZG8	924
DPH7	DPH2	Q9BQC3	892
DPH7	DPH5	Q9H2P9	874
DPH7	DPH6	Q7L8W6	853
DPH7	DPH3	Q96FX2	845
DPH7	DNAJC24	Q6P3W2	804
DPH7	TEX29	Q8N6K0	519
DPH7	RIDA	P52758	490
DPH7	ELP5	Q8TE02	484
DPH7	WDR6	Q9NNW5	479
DPH7	SERGEF	Q9UGK8	473
DPH7	DAZAP2	Q15038	468
DPH7	RNF26	Q9BY78	447
DPH7	ING5	Q8WYH8	436

IntAct

19 interactions, top by confidence:

A	B	Type	Score
CCT2	TXNDC9	psi-mi:“MI:0914”(association)	0.730
NPB	CST4	psi-mi:“MI:0914”(association)	0.530
INCA1	DPH7	psi-mi:“MI:0915”(physical association)	0.510
ZBTB33	SF3B1	psi-mi:“MI:0914”(association)	0.350
Dennd6a	IFT88	psi-mi:“MI:0914”(association)	0.350
Mis12	CTNNB1	psi-mi:“MI:0914”(association)	0.350
Chmp4b	BDP1	psi-mi:“MI:0914”(association)	0.350
XRCC1	PPIH	psi-mi:“MI:0914”(association)	0.350
PML	ATP5MF-PTCD1	psi-mi:“MI:0914”(association)	0.350
NPB	IL16	psi-mi:“MI:0914”(association)	0.350
DPH7	RALGAPA2	psi-mi:“MI:0914”(association)	0.350
DPH7	CCT2	psi-mi:“MI:0914”(association)	0.350
TEKT2	MYH1	psi-mi:“MI:0914”(association)	0.350
CCT2	WDR91	psi-mi:“MI:0914”(association)	0.350
INSR	BLTP3B	psi-mi:“MI:0914”(association)	0.350

BioGRID (59): DPH7 (Affinity Capture-RNA), DPH7 (Affinity Capture-RNA), DPH7 (Affinity Capture-RNA), DPH7 (Affinity Capture-MS), DPH7 (Affinity Capture-MS), DPH7 (Affinity Capture-MS), DPH7 (Affinity Capture-MS), DPH7 (Affinity Capture-MS), DPH7 (Affinity Capture-MS), RALGAPA2 (Affinity Capture-MS), ZNF446 (Affinity Capture-MS), RALGAPB (Affinity Capture-MS), DPH7 (Affinity Capture-MS), DPH7 (Two-hybrid), DPH7 (Reconstituted Complex)

ESM2 similar proteins: A0JN53, A4IGH4, A6H751, A6NE52, A7E3S5, A7Z052, B3NXQ7, E9Q349, E9QAM5, O95382, P0C7A1, P48760, P57081, Q05932, Q3T1I9, Q3UY23, Q4KM32, Q58CQ5, Q5EA99, Q5FVB6, Q5RB07, Q5XFW6, Q64LD2, Q6KAU8, Q6ZPG2, Q76MJ5, Q7ZVR1, Q7ZY78, Q80TE0, Q80UU1, Q8BUI3, Q8BX80, Q8C9A2, Q8NAA4, Q8NFF5, Q8NFI3, Q91ZJ0, Q924L9, Q96HA7, Q96KV7

Diamond homologs: C4JPW9, F1LTR1, O13923, O14021, O22466, O22467, O22468, O22469, O22607, O93377, O94244, O94423, P0CS36, P0CS37, P26309, P39984, P90916, P90917, Q09028, Q10G81, Q16576, Q24572, Q28D01, Q2UA71, Q2YDS1, Q3B7M6, Q3MHL3, Q3SWX8, Q4I7L0, Q4P553, Q4R304, Q4WEI5, Q54SD4, Q55E54, Q59RH5, Q5M7K4, Q5M7T1, Q5R654, Q5RF92, Q5SP67

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

107 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	1
Uncertain significance	86
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
394314	GRCh37/hg19 9q34.3(chr9:140444759-140730408)x1	Pathogenic
394948	GRCh37/hg19 9q33.2-34.3(chr9:124642754-141146461)x3	Pathogenic
2576635	GRCh37/hg19 9q34.3(chr9:140277524-140762652)x3	Likely pathogenic

SpliceAI

1699 predictions. Top by Δscore:

Variant	Effect	Δscore
9:137578620:CGCA:C	donor_loss	1.0000
9:137578621:GCACC:G	donor_loss	1.0000
9:137578622:CACCT:C	donor_loss	1.0000
9:137578623:ACC:A	donor_loss	1.0000
9:137564432:AC:A	donor_gain	0.9900
9:137564433:CC:C	donor_gain	0.9900
9:137564604:TAG:T	acceptor_gain	0.9900
9:137564959:C:CC	acceptor_gain	0.9900
9:137565152:CCC:C	acceptor_gain	0.9900
9:137565153:CCC:C	acceptor_gain	0.9900
9:137574397:C:CT	acceptor_gain	0.9900
9:137574397:C:T	acceptor_gain	0.9900
9:137574844:CTA:C	acceptor_gain	0.9900
9:137574847:C:CC	acceptor_gain	0.9900
9:137576075:CTGA:C	donor_loss	0.9900
9:137576076:TGAC:T	donor_loss	0.9900
9:137576077:GACC:G	donor_loss	0.9900
9:137576078:AC:A	donor_loss	0.9900
9:137576164:ACACC:A	acceptor_loss	0.9900
9:137576165:CAC:C	acceptor_gain	0.9900
9:137576166:ACCT:A	acceptor_loss	0.9900
9:137576168:C:CA	acceptor_loss	0.9900
9:137576169:T:C	acceptor_loss	0.9900
9:137577457:A:AC	donor_gain	0.9900
9:137577505:TTGG:T	donor_gain	0.9900
9:137564436:ATTG:A	donor_gain	0.9800
9:137564602:CATAG:C	acceptor_gain	0.9800
9:137564607:C:CC	acceptor_gain	0.9800
9:137564622:C:CT	acceptor_gain	0.9800
9:137564886:GACTC:G	donor_loss	0.9800

AlphaMissense

2973 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:137555281:G:C	F439L	0.997
9:137555281:G:T	F439L	0.997
9:137555283:A:G	F439L	0.997
9:137555287:G:C	C437W	0.997
9:137555580:A:G	W340R	0.997
9:137555580:A:T	W340R	0.997
9:137564515:A:G	W290R	0.997
9:137564515:A:T	W290R	0.997
9:137564527:A:G	W286R	0.997
9:137564527:A:T	W286R	0.997
9:137564584:A:G	W267R	0.997
9:137564584:A:T	W267R	0.997
9:137577471:A:G	W96R	0.997
9:137577471:A:T	W96R	0.997
9:137574347:A:C	S167R	0.996
9:137574347:A:T	S167R	0.996
9:137574349:T:G	S167R	0.996
9:137574774:A:G	W149R	0.996
9:137574774:A:T	W149R	0.996
9:137578678:C:A	G34W	0.996
9:137578717:A:G	W21R	0.996
9:137578717:A:T	W21R	0.996
9:137574253:A:G	W199R	0.995
9:137574253:A:T	W199R	0.995
9:137578677:C:T	G34E	0.995
9:137555588:C:T	G337E	0.994
9:137564896:C:T	G258E	0.994
9:137555288:C:T	C437Y	0.993
9:137555289:A:G	C437R	0.993
9:137564525:C:A	W286C	0.993

dbSNP variants (sampled 300 via entrez): RS1000003980 (9:137564304 G>A,C), RS1000098437 (9:137564074 C>A,T), RS1000141894 (9:137578977 C>A), RS1000239049 (9:137559425 C>CG), RS1000395484 (9:137577836 T>C), RS1000401452 (9:137578927 C>T), RS1000452613 (9:137554509 G>C), RS1000505967 (9:137555010 C>T), RS1000578224 (9:137558531 G>A), RS1000653290 (9:137558723 T>C), RS1000792830 (9:137572149 G>A), RS1000824741 (9:137554280 C>T), RS1000932174 (9:137575033 C>T), RS1001005042 (9:137568738 A>G,T), RS1001007482 (9:137559727 C>T)

Disease associations

OMIM: gene MIM:613210 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	2
Arsenic	affects methylation, affects cotreatment, increases abundance, increases expression	2
Valproic Acid	affects expression, increases expression	2
Aflatoxin B1	decreases methylation, increases methylation	2
GSK-J4	increases expression	1
pirinixic acid	affects binding, increases activity, increases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
manganese chloride	increases expression, affects cotreatment, increases abundance	1
K 7174	increases expression	1
Sunitinib	increases expression	1
Benzo(a)pyrene	affects methylation	1
Doxorubicin	affects expression	1
Manganese	increases abundance, increases expression, affects cotreatment	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Tretinoin	decreases expression	1
Cyclosporine	increases expression	1
Copper Sulfate	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer